Literature DB >> 4275598

Lymphocyte tissue culture studies on human heart transplant recipients. I. Screening recipients for serum factors which inhibit the mixed lymphocyte reaction.

A S Coulson, F MacMillan, R B Griepp, E B Stinson, E Dong, N E Shumway.   

Abstract

The sera of 20 random human heart transplant recipients, drawn before the administration of immunosuppressive medications, were screened for the presence of factors that might inhibit the mixed lymphocyte reaction. The donors for the lymphocyte cultures were unrelated both to one another and to the heart donor and recipient. Inhibition was defined as a reduction of the number of transformed cells produced in vitro to less than one-third of that produced in autologous serum. It appears that patients who have had previous heart surgery on bypass fare better with heart transplants than those who have not had surgery. This may indicate some change in the overall physiology of the former class of patients resulting in better acceptance of the transplant. In turn, this could be due to the development of a serum factor or an impairment in the patients' cellular immune systems. In the series of recipients studied, the majority possessed serum inhibitory factors possibly non-specific by-products of their heart failure. The precise nature of these factors has yet to be determined. Future research is planned to determine whether bypass surgery is responsible for the stimulation of new immuno-depressive factors or if in some way it boosts the titer of pre-existing factors.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4275598      PMCID: PMC1355928          DOI: 10.1097/00000658-197406000-00020

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  Macrophage-like properties of some guinea-pig transformed cells.

Authors:  A S Coulson; B W Gurner; R R Coombs
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

Review 2.  Immunological enhancement as studied by cell culture techniques.

Authors:  K E Hellström; I Hellström
Journal:  Annu Rev Microbiol       Date:  1970       Impact factor: 15.500

3.  Cardiac transplantation in man. VII. Cardiac allograft pathology.

Authors:  C P Bieber; E B Stinson; N E Shumway; R Payne; J Kosek
Journal:  Circulation       Date:  1970-05       Impact factor: 29.690

4.  Cardiac transplantation in man. 3. Surgical aspects.

Authors:  E B Stinson; E Dong; A B Iben; N E Shumway
Journal:  Am J Surg       Date:  1969-08       Impact factor: 2.565

5.  Recognition pathway in lymphocytes.

Authors:  A S Coulson
Journal:  J Theor Biol       Date:  1969-10       Impact factor: 2.691

6.  Inhibition of the response in mixed leukocyte cultures by alloimmune plasma.

Authors:  F C Grumet; B G Leventhal
Journal:  Transplantation       Date:  1970-04       Impact factor: 4.939

7.  "Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation.

Authors:  D C Dumonde; R A Wolstencroft; G S Panayi; M Matthew; J Morley; W T Howson
Journal:  Nature       Date:  1969-10-04       Impact factor: 49.962

8.  Inhibition of PHA-stimulated lymphocyte transformation by plasma from patients with advanced alcoholic cirrhosis.

Authors:  C C Hsu; C M Leevy
Journal:  Clin Exp Immunol       Date:  1971-05       Impact factor: 4.330

9.  Quantitation of peripheral blood lymphocyte cultures.

Authors:  A S Coulson; D G Chalmers
Journal:  Nature       Date:  1966-01-22       Impact factor: 49.962

10.  Immunologically stimulated human peripheral blood lymphocytes in vitro. II. Mixed lymphocyte cultures with related and unrelated donors.

Authors:  D G Chalmers; A S Coulson; C Evans; S Yealland
Journal:  Int Arch Allergy Appl Immunol       Date:  1966
View more
  1 in total

1.  Lymphocyte tissue culture studies on human heart transplant recipients. III. Prediction of outcome of transplantation based on immunologic studies.

Authors:  A S Coulson; V H Zeitman; C Struthers; E Dong; E B Stinson; R B Griepp; R B Cohn; N E Shumway
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.